Bispecific antibodies mimicking factor VIII in hemophilia A: converting innovation to an essential medicine

Preventive subcutaneous treatment of severe hemophilia A with bispecific antibodies that mimic the action of coagulation factor VIII (FVIII) is emerging as an effective alternative to replacement therapy with intravenous administration of FVIII concentrates, either derived from plasma or produced by...

Descripción completa

Detalles Bibliográficos
Autores principales: Hermans, Cedric, Pierce, Glenn F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Forum
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394560/
https://www.ncbi.nlm.nih.gov/pubmed/37538493
http://dx.doi.org/10.1016/j.rpth.2023.100173

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394560/
https://www.ncbi.nlm.nih.gov/pubmed/37538493
http://dx.doi.org/10.1016/j.rpth.2023.100173

Ejemplares similares